The historical rank and industry rank for Moberg Pharma AB's FCF Margin % or its related term are showing as below:
FRA:MB8'
s FCF Margin % Range Over the Past 10 Years
Min: -41021.26 Med: -115.18 Max: 7.78
Current: -305.16
During the past 13 years, the highest FCF Margin % of Moberg Pharma AB was 7.78%. The lowest was -41021.26%. And the median was -115.18%.
FRA:MB8's FCF Margin % is ranked worse than 95.09% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs FRA:MB8: -305.16
Moberg Pharma AB FCF Margin % Related Terms
Moberg Pharma AB FCF Margin % Historical Data
* Premium members only.
The historical data trend for Moberg Pharma AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moberg Pharma AB FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Moberg Pharma AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moberg Pharma AB (FRA:MB8) has a FCF Margin % of -163.24% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Moberg Pharma AB and its competitors. According to the industry distribution chart, Moberg Pharma AB ranks #911 out of 958 companies in the Drug Manufacturers industry, placing it in the top 95.1%.
Is Moberg Pharma AB's FCF Margin % too high?
Moberg Pharma AB's current FCF Margin % is -163.24%. Based on the distribution chart, Moberg Pharma AB ranks #911 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #911 out of 958 companies for FCF Margin %. This places Moberg Pharma AB in the lower half of its industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Moberg Pharma AB and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moberg Pharma AB's current FCF Margin % is -163.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current FCF Margin % of -163.24%. The stock's GF Value™ is €1.09, compared to a current price of €0.79 — trading 27.6% below its estimated fair value. The current FCF Margin % is -163.24%. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current FCF Margin % is -163.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?
Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued.
The current stock price of €0.79 is trading 27.6% below its estimated GF Value™ of €1.09.
Key valuation signals for FRA:MB8:
FCF Margin %: -163.24%
GF Value™: €1.09 vs. price of €0.79 (27.6% below fair value)
No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score
Get the complete analysis for FRA:MB8
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MB8 has been successfully added to your 
